A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP
The purpose of this study is to learn if the study drug, which is used to treat inflammation, is both safe and beneficial in reducing future cardiovascular events in subjects who have ongoing increased inflammation. This study will also test whether or not the study drug reduces the development of Type 2 diabetes (often called adult onset diabetes).
Heart attack with increased inflammation in the blood vessels of the heart.
Includes (but not limited to):
-Male or female age 18+
-Have experienced a documented heart attack
-Not currently scheduled or planning to have any major surgical procedure
-Negative test results for HIV (human immunodeficiency virus), Hepatitis B or C (viral infections that affect the liver), or TB (tuberculosis)
18 - 90
Healthy Volunteers Needed
Duration of Participation
Up to 6 years
Susan Dean, RN, BSN, MPH, CCRC
Subjects will receive $75 per study visit completed